Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 973 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer July 26, 2018 Trial Results Support SBRT as a Standard Option for Some Prostate... November 21, 2024 Her Cancer Surgery Was Postponed Due To The COVID-19 Pandemic —... July 7, 2020 Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... May 17, 2024 Load more HOT NEWS Registry Findings Highlight the Importance of Interdisciplinary Care in Rheumatic irAEs... Metastasis Likely Caused by Lack of Oxygen in Cancerous Tumors, Study... How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert... Blood Test for Early Detection of Cancer: Final Study Results Support...
